COMPANY OVERVIEW
Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including: Novartis, Amgen, Merck, Pfizer, Baxter International and Eli Lilly.

RECENT NEWS
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Jan 13 2020, 4:02 PM EST

STOCK OVERVIEW

| Symbol | LGND |
| Exchange | Nasdaq |
| Market Cap | |
| Last Price | $0.00 |
| 52-Week Range | $0.00 - $0.00 |

INVESTOR RELATIONS
3911 Sorrento Valley Boulevard
Suite 110
San Diego, CA 92121
T: 858-550-7893
investors@ligand.com

DISCLAIMER
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.